ISTC annually organizes the workshops on the initiative of the Scientific Advisory Committee of ISTC to create a platform for the experts in different spheres to share experiences.

In 2015 it was proposed by SAC members to held a joint ISTC - STCU - Fondation Mérieux health Workshop on Emerging and Reemerging Infectious Diseases in France to involve experts not only from CIS countries and Georgia, but also from EU, USA, Afghanistan, Pakistan, Mongolia and Moldova. 

The main purpose of the Workshop was to discuss trends and problems in infectious disease control in Europe and CIS countries. 

The presentations of scientific achievements were divided into three thematic sessions: 
(i) Emerging Infectious diseases: a continuous and global threat
(ii) Hepatitis B (HBV) and Hepatitis C (HCV) and 
(iii) Multidrug-resistant Tuberculosis

Session 1 - Emerging Infectious diseases: a continuous and global threat
Scientists recognize the challenges societies face regarding these threats that largely come from animals. The solution for effective interventions requires collaborative efforts of multiple disciplines to address human-animal- ecosystem interface.
This session provided an opportunity to discuss issues related to the risks factors for emergence of Filoviruses and Respiratory viruses.

Session 2 - Hepatitis B (HBV) and Hepatitis C (HCV)
Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) remain a major public health problem worldwide. The current research priorities for chronic hepatitis B and C are evolving differently: major achievements have been accomplished in the development of direct-acting antivirals for HCV whereas for HBV, despite the availability of an efficient vaccine, there are still more than 250 million chronic carriers worldwide.
The development of true combination therapy to "cure" HBV infection and issues related to access to treatment at the global level were discussed during session 2. 

Session 3 - Multidrug-resistant Tuberculosis (MDR-TB)
Most people with tuberculosis can be cured by a strictly followed drug regimen. However, inappropriate or incorrect use of antimicrobial drugs, use of ineffective formulations of drugs, and premature treatment interruption can cause drug resistance.
In some countries, it is becoming increasingly difficult to treat MDR-TB. Treatment options are limited and expensive, recommended medicines are not always available, and patients experience many adverse effects from the drugs. In some cases even more severe drug-resistant tuberculosis may develop. Extensively drug-resistant TB, XDR-TB, is a form of multidrug-resistant tuberculosis with additional resistance to more anti-TB drugs that therefore responds to even fewer available medicines. It has been reported in 100 countries worldwide.

Presentations (Download)
Program and list of participants (Download)